BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mayne Pharma USA Inc. Announces FDA Approval Of Mitoxantrone


4/12/2006 10:27:04 AM

PARAMUS, N.J., April 11 /PRNewswire/ -- Mayne Pharma (USA) Inc. announces that the US Food and Drug Administration (FDA) has granted final approval for the company's Abbreviated New Drug Application for Mitoxantrone Injection, USP packaged in 20mg, 25mg and 30mg multiple-dose presentations.

Mitoxantrone is a generic equivalent to Serono's Novantrone(R) which generated annual sales of approximately $75 million in 2005.

Mitoxantrone is expected to be a strong addition to Mayne's existing business in the U.S. and further enhance the range of oncology and hospital-specific specialty products sold in the region.

Mayne Pharma is a global specialty pharmaceutical and health care company. It has offices in 20 countries and distributes in over 30 others, with major operations in the USA, Canada, the UK and Australia. Mayne Pharma's U.S. division specializes in generic injectable pharmaceuticals in a number of defined therapeutic areas, including oncology and anesthesia/pain management, as well as drugs for the treatment of cardiac conditions and to combat hypertension.

06006B

Mayne Pharma (USA) Inc.

CONTACT: David Tantillo, +1-201-225-5572, for Mayne Pharma (USA) Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES